Kiminori Terui
Overview
Explore the profile of Kiminori Terui including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
104
Citations
958
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kato S, Nakashima K, Yamato G, Saito S, Taneyama Y, Yamamoto N, et al.
Pediatr Blood Cancer
. 2024 Aug;
71(10):e31244.
PMID: 39099137
Hypomethylating agent treatment for myeloid leukemia associated with Down syndrome (ML-DS) has been scarcely reported. Herein, we collected information on azacitidine treatment for ML-DS in Japan. Forty-eight cycles of azacitidine...
2.
Nagai K, Mitani T, Kato M, Kojima K, Fukushima N, Omaeuda T, et al.
Pediatr Blood Cancer
. 2024 Aug;
71(10):e31228.
PMID: 39090683
No abstract available.
3.
Yamato G, Tsumura Y, Muramatsu H, Shimada A, Imaizumi T, Tsukagoshi H, et al.
Blood Adv
. 2024 May;
8(12):3120-3129.
PMID: 38691583
Transient abnormal myelopoiesis (TAM) occurs in 10% of neonates with Down syndrome (DS). Although most patients show spontaneous resolution of TAM, early death occurs in ∼20% of cases. Therefore, new...
4.
Ishida H, Kawahara Y, Tomizawa D, Okamoto Y, Hama A, Cho Y, et al.
J Hematol Oncol
. 2024 Apr;
17(1):24.
PMID: 38679709
Although killer Ig-like receptor ligands (KIR-L) mismatch has been associated with alloreactive natural killer cell activity and potent graft-versus-leukemia (GVL) effect among adults with acute myeloid leukemia (AML), its role...
5.
Iyoda S, Yoshida K, Shoji K, Ito N, Tanaka M, Nannya Y, et al.
Leukemia
. 2024 Apr;
38(7):1609-1612.
PMID: 38632314
No abstract available.
6.
Sato T, Yoshida K, Toki T, Kanezaki R, Terui K, Saiki R, et al.
Blood
. 2024 Mar;
143(25):2627-2643.
PMID: 38513239
Transient abnormal myelopoiesis (TAM) is a common complication in newborns with Down syndrome (DS). It commonly progresses to myeloid leukemia (ML-DS) after spontaneous regression. In contrast to the favorable prognosis...
7.
Sano H, Fukushima K, Yano M, Osone S, Kato Y, Hasegawa D, et al.
Int J Hematol
. 2024 Mar;
119(6):745-754.
PMID: 38460081
The dosage of chemotherapy drugs for overweight/obese children with acute myeloid leukemia (AML) has been empirically reduced based on ideal body weight (BW) in Japan to reduce the risk of...
8.
Tanaka T, Kudo K, Kanezaki R, Yuzawa K, Toki T, Okuse R, et al.
Exp Hematol
. 2024 Feb;
132:104179.
PMID: 38342295
Myeloid leukemia associated with Down syndrome (ML-DS) responds well to chemotherapy and has a favorable prognosis, but the clinical outcome of patients with refractory or relapsed ML-DS is dismal. We...
9.
Yamashita M, Tomoda T, Mizuo A, Isoda T, Egawa M, Yoshida M, et al.
Pediatr Blood Cancer
. 2023 Dec;
71(3):e30834.
PMID: 38149846
Diamond-Blackfan anemia (DBA) is a congenital anemia with erythroid cell aplasia. Most of the causative genes are ribosomal proteins. GATA1, a hematopoietic master transcription factor required for erythropoiesis, also causes...
10.
Tomizawa D, Matsubayashi J, Iwamoto S, Hiramatsu H, Hasegawa D, Moritake H, et al.
Leukemia
. 2023 Nov;
38(1):202-206.
PMID: 37926712
No abstract available.